Vor Biopharma is advancing blood cancer treatments with innovative technologies, focusing on improving care for AML, MDS, and MPN by making stem cells resistant. This method has shown promise, especially for post-transplant AML treatments. Wedbush analyst David Nierengarten is optimistic about the VBP301 trial, highlighting superior outcomes with VCAR33ALLO over autologous therapies, recommending an Outperform rating with an $11 price target. The broader consensus supports a Strong Buy rating, foreseeing significant stock appreciation to $14.42. In the short term, I'm looking for the stock to accumulate at slightly lower levels before working to the upside ($3 area), if we break through that zone we can see much higher, depending on catalysts, influenced by past positive pipeline PR. Good luck everyone.
Catalyst: Vor Biopharma has initiated a phase I/II trial of VCAR33ALLO, a donor-derived CAR-T therapy for relapsed/refractory acute myeloid leukemia (AML), with results anticipated in the second half of 2024.
Catalyst: Vor Biopharma has initiated a phase I/II trial of VCAR33ALLO, a donor-derived CAR-T therapy for relapsed/refractory acute myeloid leukemia (AML), with results anticipated in the second half of 2024.